News
Royalty Pharma published press releases by date and/or category
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
NEW YORK, NY, October 11, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open.
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
NEW YORK, NY, September 21, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee.
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
NEW YORK, NY, and COPENHAGEN, DENMARK, September 5, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue.
Royalty Pharma To Present at Upcoming Investor Conferences
NEW YORK, NY, September 5, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 18 th Annual BioPharma Conference on Wednesday, September 6 at 11:20 a.m.
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement For New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-VNCG)
NEW YORK, NY, and SAINT PREX, SWITZERLAND, August 24, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s
Royalty Pharma Reports Second Quarter 2023 Results
NEW YORK, NY, August 8, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
NEW YORK, NY, July 18, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. financial markets open.
Royalty Pharma Declares Third Quarter 2023 Dividend
NEW YORK, NY, July 17, 2023 - The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share.
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
NEW YORK, NY, June 7, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44 th Annual Global Healthcare Conference on June 13, 2023 at 5:00 p.m. ET / 2:00 p.m. PT. The webcast will be accessible from Royalty Pharma’s “Events” page at
